About this trial
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.
This retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.
Eligibility criteria
Qualifiers
Patients aged ≥18 years
LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands
Histopathological results (biopsy or excision) and/or 6-12 month clinical follow-up data available
Disqualifiers
Patients <18 years of age
Cases without histopathological confirmation or available follow-up data
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Maastricht University Medical Center
Lead sponsor
Mohs Klinieken
Collaborator